Delivery Order SPE2DB20D3101-SPE2DB23FQSP3

Award Date 10/12/22
Potential Completion Date 10/13/22
Potential Value $4.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $7,422.95, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of REBIF REBIDOSE 44 MCG/0.5 ML 0.5ML, a specialty medication, with a completion date of August 14, 2024. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,054.32 delivery order is for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a prescription medication. The contract has an ultimate completion date of April 24, 2023 and is a firm fixed-price arrangement. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,540.37, is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product. This is a delivery order contract, with a firm fixed-price pricing type, and an ultimate completion date of December 18, 2024. The contract does not have a set-aside designation, indicating open...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $31,971.06 for the medical product REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The award has an ultimate completion date of January 13, 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 that serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $64,142.21, is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of June 26, 2024 and is a firm fixed-price delivery order. No set-aside designation was used for this award. AmerisourceBergen holds a significant...
This federal contract award, valued at $12,303.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the provision of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication. The contract has an ultimate completion date of October 21, 2024 and does not have a set-aside designation, indicating open competition. Amerisourcebergen, the prime contractor, is a...
This federal contract award, valued at $21,075.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The contract covers the procurement of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication, to support military healthcare programs. As a general...
This federal contract award, valued at $16,695.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order (DO) under the DLA's Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $278,847.16, is a delivery order under the company's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and...
This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,646.17 firm fixed-price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 7, 2022, with a completion date of July 8, 2022. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical to...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB23FQSP3
    Delivery Order

This federal contract award, valued at $4,664.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication.

The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at $999,999,999 and runs through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

Generated 2/27/25, 10:41 AM